Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in December

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a decline of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is presently 4.6 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Stock Performance

Shares of GOSS stock traded down $0.04 during mid-day trading on Friday, reaching $0.96. The company’s stock had a trading volume of 817,985 shares, compared to its average volume of 1,082,774. The company’s 50 day simple moving average is $0.84 and its 200-day simple moving average is $0.91. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. Research analysts predict that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

Large investors have recently bought and sold shares of the company. NEA Management Company LLC grew its holdings in Gossamer Bio by 14.2% during the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after acquiring an additional 2,103,766 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Gossamer Bio by 204.7% during the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after acquiring an additional 1,375,000 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Gossamer Bio by 30.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after acquiring an additional 442,895 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Gossamer Bio by 67.4% in the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after purchasing an additional 124,913 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.